BriaCell Therapeutics Corp. (TSX:BCT)

Market Cap	10.98M
Revenue (ttm)	n/a
Net Income (ttm)	-40.23M
Shares Out	1.88M
EPS (ttm)	-47.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,120
Average Volume	37,795
Open	5.95
Previous Close	5.83
Day's Range	5.91 - 6.26
52-Week Range	5.70 - 135.00
Beta	1.90
RSI	37.36
Earnings Date	Mar 13, 2026

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore Co...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: William Williams
• Employees: 16
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: BCT

Financial Performance

Financial numbers in USD